您当前所在的位置:首页 > 产品中心 > 产品信息
Allopurinol_分子结构_CAS_315-30-0)
点击图片或这里关闭

Allopurinol

产品号 DB00437 公司名称 DrugBank
CAS号 315-30-0 公司网站 http://www.ualberta.ca/
分子式 C5H4N4O 电 话 (780) 492-3111
分子量 136.11146 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 320

产品价格信息

请登录

产品别名

标题
Allopurinol
IUPAC标准名
1H,2H,4H-pyrazolo[3,4-d]pyrimidin-4-one
IUPAC传统名
ALLO
商标名
Embarin
Atisuril
Apurin
Urbol
Alositol
Lopurin
7HP
Ailural
Apurol
Bloxanth
Nektrohan
Purinol
Remid
Uriprim
Uritas
Xanturat
Zyloric
Adenock
Allopur
Allozym
Aloral
Aluline
Anoprolin
Anzief
Bleminol
Cellidrin
Cosuric
Dabroson
Foligan
HPP
Hamarin
Hexanuret
Takanarumin
Uricemil
Uripurinol
Urolit
Urosin
Urtias
Urtias 100
Allo-Puren
Allural
Aloprim
Apo-Allopurinol
Apulonga
Caplenal
Dabrosin
Dura Al
Epidropal
Epuric
Geapur
Gichtex
Gotax
Ketanrift
Ketobun-A
Ledopur
Lysuron
Milurit
Miniplanor
Monarch
Progout
Riball
Sigapurol
Suspendol
Urobenyl
Zyloprim
Allohexal
别名
Alopurinol [INN-Spanish]
Allopurinolum [INN-Latin]
Allopurinol Sodium

产品登记号

PubChem SID 46508516
CAS号 315-30-0
PubChem CID 2094

产品性质

疏水性(logP) -1
溶解度 569 mg/L

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [PubChem]
Indication For the treatment of hyperuricemia associated with primary or secondary gout. Also indicated for the treatment of primary or secondary uric acid nephropathy, with or without the symptoms of gout, as well as chemotherapy-induced hyperuricemia and recurrent renal calculi.
Pharmacology Allopurinol, a structural analog of the natural purine base hypoxanthine, is used to prevent gout and renal calculi due to either uric acid or calcium oxalate and to treat uric acid nephropathy, hyperuricemia, and some solid tumors.
Toxicity LD50=214 mg/kg (in mice)
Affected Organisms
Humans and other mammals
Biotransformation Hepatic
Absorption Approximately 80-90% absorbed from the gastrointestinal tract.
Half Life 1-3 hours
Protein Binding Allopurinol and oxypurinol are not bound to plasma proteins
Elimination Approximately 20% of the ingested allopurinol is excreted in the feces.
References
Pacher P, Nivorozhkin A, Szabo C: Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006 Mar;58(1):87-114. [Pubmed]
Schlesinger N: Diagnosing and treating gout: a review to aid primary care physicians. Postgrad Med. 2010 Mar;122(2):157-61. [Pubmed]
Suzuki I, Yamauchi T, Onuma M, Nozaki S: Allopurinol, an inhibitor of uric acid synthesis--can it be used for the treatment of metabolic syndrome and related disorders? Drugs Today (Barc). 2009 May;45(5):363-78. [Pubmed]
Terkeltaub R: Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010 Jan;6(1):30-8. [Pubmed]
George J, Struthers AD: Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag. 2009;5(1):265-72. Epub 2009 Apr 8. [Pubmed]
External Links
Wikipedia
RxList
PDRhealth
Drugs.com

参考文献

  • Pacher P, Nivorozhkin A, Szabo C: Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006 Mar;58(1):87-114. Pubmed
  • Schlesinger N: Diagnosing and treating gout: a review to aid primary care physicians. Postgrad Med. 2010 Mar;122(2):157-61. Pubmed
  • Suzuki I, Yamauchi T, Onuma M, Nozaki S: Allopurinol, an inhibitor of uric acid synthesis--can it be used for the treatment of metabolic syndrome and related disorders? Drugs Today (Barc). 2009 May;45(5):363-78. Pubmed
  • Terkeltaub R: Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010 Jan;6(1):30-8. Pubmed
  • George J, Struthers AD: Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag. 2009;5(1):265-72. Epub 2009 Apr 8. Pubmed